Pacer Advisors
ADVM

Pacer Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Pacer Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-570
Closed -$56K – 1397
2021
Q1 		$56K Buy
570
+35
+7% +$4.2K ﹤0.01% 1429
2020
Q4 		$58K Buy
535
+154
+40% +$19.1K ﹤0.01% 1403
2020
Q3 		$39K Buy
+381
New +$57.1K ﹤0.01% 1313

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pacer Advisors's ADVM Position: Q2 2021 in Review

Pacer Advisors sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 570 shares — an estimated $56K sold.

Pacer Advisors first reported a position in ADVM in Q3 2020 and held it in 3 quarters. The position peaked at $58K in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Pacer Advisors reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 570 Adverum Biotechnologies shares in Q2 2021, an estimated $56K.
  • Pacer Advisors first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 3 quarters.
  • Pacer Advisors's Adverum Biotechnologies position peaked at $58K in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.